The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease-Reference-Cited by-同舟云学术

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease

Published:2020-07-17 Issue:29 Volume:99 Page:e21226
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Ishida Natsuki,Miyazu Takahiro,Sugiyama Tomohiro,Tamura Satoshi,Kagami Takuma,Tani Shinya,Yamade Mihoko,Iwaizumi Moriya,Hamaya Yasushi,Osawa Satoshi,Furuta Takahisa,Sugimoto Ken

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference37 articles.

1. Targeting TNF-α for the treatment of inflammatory bowel disease;Billiet;Expert Opin Biol Ther,2014

2. Update on anti-tumor necrosis factor agents in Crohn disease;Singh;Gastroenterol Clin North Am,2014

3. ACCENT I Study Group: maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

4. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004

5. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective;Wu;Value Health,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

2. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

3. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy;World Journal of Gastroenterology;2022-06-21

4. Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD;European Journal of Hospital Pharmacy;2022-02-25

5. Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements;British Journal of Clinical Pharmacology;2020-12-07